Clinical Trial Update: Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating fluzoparib combined with camrelizumab as maintenance therapy in locally advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• Fluzoparib (fluzoparib)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN